Stock 2196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:42 2024-06-28 EDT 		5-day change 1st Jan Change
13.22 HKD +0.46% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. -0.60% -22.24%
06-28 Shanghai Fosun Pharmaceutical Gets Registration Application Approval for Chest Pain Drug MT
06-26 Shanghai Fosun Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Shanghai Fosun Pharmaceutical Gets Registration Application Approval for Chest Pain Drug
MT
Shanghai Fosun Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024
CI
Henlius Biotech Shares Surge After Fosun's Buyout Offer
DJ
Fosun Pharma Signs HK$13.4 Billion Merger Offer for Henlius Biotech; Henlius Shares Soar 19%
MT
Shanghai Fosun Pharmaceutical Co., Ltd. agreed to acquire 40.44% stake in Shanghai Henlius Biotech, Inc..
CI
Fosun Pharma Trims Stake in Gland Pharma to 51.83%
MT
Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3%
MT
Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7%
MT
China Approves Clinical Trials For Breast Cancer Drugs
MT
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets
MT
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug
MT
Fosun Pharma's Q1 Profit Slumps 38%
MT
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.
CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates
MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. 2196 Stock
  5. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Highlights